About that lack of Alzheimer’s drugs
Just as the cupboard of experimental therapies for Alzheimer’s from major drug companies looks pretty bare (notwithstanding Biogen’s aforementioned and controversial revival), there was a surprise over the weekend. Chinese regulators conditionally approved Oligomannate, a drug derived from seaweed and made by Shanghai Green Valley Pharmaceuticals.
The company said a Phase 3 trial demonstrated the drug slowed cognitive decline compared to placebo, and that it has plans to run another, global Phase 3 trial so it can file for approval in other countries. But the company hasn’t published the full data yet, and some outside experts expressed some caution. One key question: Just how much of an effect did the drug have on cognitive function?
In addition to being the first Alzheimer’s drug approved since 2003, Oligomannate stands out because it was designed to affect the neuroinflammation that some scientists think contributes to Alzheimer’s through modulating the gut microbiome. An amyloid clearing drug this is not.
Read more.
The company said a Phase 3 trial demonstrated the drug slowed cognitive decline compared to placebo, and that it has plans to run another, global Phase 3 trial so it can file for approval in other countries. But the company hasn’t published the full data yet, and some outside experts expressed some caution. One key question: Just how much of an effect did the drug have on cognitive function?
In addition to being the first Alzheimer’s drug approved since 2003, Oligomannate stands out because it was designed to affect the neuroinflammation that some scientists think contributes to Alzheimer’s through modulating the gut microbiome. An amyloid clearing drug this is not.
Read more.
No hay comentarios:
Publicar un comentario